Giulia C. Kennedy - 05 Aug 2022 Form 4 Insider Report for VERACYTE, INC. (VCYT)

Role
Chief Scientific & Med Officer
Signature
/s/ Jonathan Wygant as attorney-in-fact
Issuer symbol
VCYT
Transactions as of
05 Aug 2022
Net transactions value
-$27,244
Form type
4
Filing time
09 Aug 2022, 17:16:29 UTC
Previous filing
06 Jun 2022
Next filing
07 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCYT Common Stock Award $0 +10,702 +18% $0.000000 71,055 05 Aug 2022 Direct F1
transaction VCYT Common Stock Options Exercise $20.9 +2 +0% $10.45 71,057 05 Aug 2022 Direct F2
transaction VCYT Common Stock Options Exercise $12.9 +2 +0% $6.45 71,059 05 Aug 2022 Direct F2
transaction VCYT Common Stock Options Exercise $5.43 +1 +0% $5.43 71,060 05 Aug 2022 Direct F2
transaction VCYT Common Stock Sale $27,283 -1,028 -1.4% $26.54 70,032 05 Aug 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCYT Stock Option (right to buy) Award $0 +18,248 $0.000000 18,248 05 Aug 2022 Common Stock 18,248 $27.90 Direct F3
transaction VCYT Stock Option (right to buy) Options Exercise $0 -2 -100% $0.000000* 0 05 Aug 2022 Common Stock 2 $10.45 Direct F2, F4
transaction VCYT Stock Option (right to buy) Options Exercise $0 -2 -100% $0.000000* 0 05 Aug 2022 Common Stock 2 $6.45 Direct F2, F4
transaction VCYT Stock Option (right to buy) Options Exercise $0 -1 -100% $0.000000* 0 05 Aug 2022 Common Stock 1 $5.43 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units awarded on August 5, 2022 vest 1/3rd on September 2, 2023 and 1/12th per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.
F2 The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022.
F3 The option becomes exercisable as to 1/3rd of the shares on August 5, 2023, and the remaining shares vest at a rate of 1/36th of the total number of shares subject to the award for each month of continuous service thereafter.
F4 The option is fully vested.